Prasso Jason E, Deng Jane C
Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, 10833 Le Conte Avenue, CHS 37-131, Los Angeles, CA 90095, USA.
Division of Pulmonary and Critical Care Medicine, Veterans Affairs Healthcare System, University of Michigan, 2215 Fuller Road, 111G Pulmonary, Ann Arbor, MI 48105, USA.
Clin Chest Med. 2017 Mar;38(1):127-138. doi: 10.1016/j.ccm.2016.11.006. Epub 2016 Dec 13.
Secondary bacterial pneumonia after viral respiratory infection remains a significant source of morbidity and mortality. Susceptibility is mediated by a variety of viral and bacterial factors, and complex interactions with the host immune system. Prevention and treatment strategies are limited to influenza vaccination and antibiotics/antivirals respectively. Novel approaches to identifying the individuals with influenza who are at increased risk for secondary bacterial pneumonias are urgently needed. Given the threat of further pandemics and the heightened prevalence of these viruses, more research into the immunologic mechanisms of this disease is warranted with the hope of discovering new potential therapies.
病毒性呼吸道感染后的继发性细菌性肺炎仍然是发病和死亡的重要原因。易感性由多种病毒和细菌因素以及与宿主免疫系统的复杂相互作用介导。预防和治疗策略分别限于流感疫苗接种和使用抗生素/抗病毒药物。迫切需要新的方法来识别流感患者中继发性细菌性肺炎风险增加的个体。鉴于未来大流行的威胁以及这些病毒的高流行率，有必要对这种疾病的免疫机制进行更多研究，以期发现新的潜在治疗方法。
